Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 251-256

  Johnston, Stephen R D ^a   Lu, Biao ^b   Scott, Gary K ^b   Kushner, Peter J ^c   Smith, Ian E ^a   Dowsett, Mitchell ^a   Benz, Christopher C ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CHEMOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DNA, NEOPLASM; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTORS, ESTROGEN; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1;

EID: 0033049975     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gottardis, M., and Jordan, V. C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res., 48: 5183-5187, 1988.
2. Howell, A., DeFriend, D., and Anderson E. Mechanisms of response and resistance to endocrine therapy for breast cancer and the development of new treatments. Rev. Endocr. Rel. Cancer, 43: 5-21, 1993.
3. Johnston, S. R. D., Saccani-Jotti, G., Smith, I. E., Salter, J., Newby, J., Copper, M., Ebbs, S. R., and Dowsett, M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res., 55: 3331-3338, 1995.
4. Johnston, S. R. D., Lu, B., Dowsett, M., Liang, X., Kaufmann, M., Scott, G. K., Osborne, C. K., and Benz, C. C. Comparison of estrogen receptor DNA-binding in untreated and acquired antiestrogen-resistant human breast tumors. Cancer Res., 57: 3723-3727, 1997.
5. Johnston, S. R. D. Acquired tamoxifen resistance in human breast cancer: potential mechanisms and clinical implications. Anti-Cancer Drugs, 8: 911-930, 1997.
6. Angel, P., and Karin, M. The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim. Biophys. Acta, 1072: 129-157, 1991.
7. Karin, M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem., 270: 16483-16486, 1995.
8. Gupta, S., Barrett, T., Whitmarsh, A. J., Cavanagh, J., Sluss, H. K., Derijard, B., and Davis, R. J. Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J., 15: 2760-2770, 1996.
9. Webb, P., Lopez, G. N., Uht, R. M., and Kushner, P. J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol., 9: 443-456, 1995.
10. Dumont, J. A., Bitoni, A. J., Wallace, C. D., Baumann, R. J., Cashman, E. A., and Cross-Doersen, D. E. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ., 7: 351-359, 1996.
11. Wise, S. C., Smith, L. M., Hendricks, D. T., Sabichi, A. L., Bober, M., Brown, P. H., and Birrer, M. J. Over-expression of the c-jun oncoprotein in the human breast cancer cell line MCF-7 results in tamoxifen resistance and increased invasiveness. Proc. Am. Assoc. Cancer Res., 38: 173, 1997.
12. Chen, T. K., Smith, L. M., Gebhardt, D. K., Birrer, M. J., and Brown, P. H. Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol. Carcinog., 15: 215-226, 1996.
13. Gaub M-P, Bellard, M., Scheuer, I., Chambon, P., and Sassone-Corsi, P. Activation of the ovalbumin gene by estrogen receptor involves Fos-Jun complex. Cell, 63: 1267-1276, 1990.
14. Phillips, A., Chalbos, D., and Rochefort H. Estradiol increases and anti-estrogens antagonize the growth-factor induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis. J. Biol. Chem., 19: 14103-14108, 1993.
15. Umayahara, Y., Kawamori, R., Wateda, H., Imano, E., Iwama, N., Morishima, T., Yamasaki, Y., Kajimoto, Y., and Kamada, T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J. Biol. Chem., 269: 16433-16442, 1994.
16. Phillips, A., Teyssier, C., Galtien, F., Rivier-Covas, C., Rey J-M. Rochefort, H., and Chalbos, D. FRA-1 expression level modulates regulation by activator protein-1 activity by estradiol in breast cancer cells. Mol. Endocrinol., 12: 973-985, 1998.
17. Astruc, M. E., Chabret, C., Bali, P., Gagne, D., and Pons, M. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: involvement of the estrogen receptor. Endocrinology, 136: 824-832, 1995.
18. Osborne, C. K., Coronado, E. B., and Robinson, J. P. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term anti-oestrogen therapy. Eur. J. Cancer Clin. Oncol., 23: 1189-1196, 1987.
19. Schiff, R., Reddy, P., Coronado, E., Grim, M., Hilsenbeck, S., Fuqua, S., Brown, P. H., and Osborne, C. K. Development of tamoxifen-stimulated growth in vivo is associated with changes in AP-1 activity. Breast Cancer Res. Treat., 46: A347, 1997.
20. Hibi, M., Lin, A., Smeal, T., Minden, A., and Karin, M. Identification of an oncoprotein and UV-responsive protein kinase that bind and potentiate the c-jun activation domain. Genes Dev., 7: 2135-2148, 1993.
21. Derijard, B., Hibi, M., Wu I-H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. JNK1: a protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-jun activation domain. Cell, 76: 1025-1037, 1994.
22. Kyriakis, J. M., Banerjee, P., Nikolakaki, E., Dai, T., Rubie, E. A., Ahmad, M. F., Auruch, J., and Woodgett, J. R. The stress-activated protein kinase subfamily of c-Jun kinases. Nature (Lond.), 369: 156-160, 1994.
23. Dai, T., Rubie, E., Franklin, C. C., Kraft, A., Gillespie, D. A., Avruch, J., Kynakis, J. M., and Woodgett, J. R. Stress-activated protein kinases bind directly to the d domain of c-Jun in resting cells: implications for repression of c-Jun function. Oncogene, 10: 849-855, 1995.
24. Logan, S. K., Falasca, M., Hu, P., and Schlessinger, J. Phosphatidylinositol 3-kinase mediates epidermal growth factor-induced activation of the c-Jun N-terminal kinase signalling pathway. Mol. Cell. Biol., 17: 5784-5790, 1997.
25. Gupta, S., Campbell, D., Derijard, B., and Davis, R. J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science (Washington DC), 267: 389-393, 1995.
26. Gille, H., Strahl, T., and Shaw, P. E. Activation of ternary complex factor Elk-1 by stress activated protein kinases. Curr. Biol., 5: 1191-1200. 1995.
27. Newby, J. C., Johnston, S. R. D., Smith, I. E., and Dowsett M. Expression of epidermal growth factor and c-erbB2 during the development of tamoxifen resistance in human breast cancer. Clin. Cancer Res., 3: 1643-1651, 1997.
28. Enmark, E., Pelo-Huikko, M., Grandien, K., Lagercrantz, S., Lagercrantz, J., Fried, G., Nordenskjold, M., and Gustafsson, J-A. Human estrogen receptor b-gene structure, chromosomal localisation, and expression pattern. J. Clin. Endocrinol. Metab., 82: 4258-4265, 1997.
29. Paech, K., Webb, P., Kuiper, G. G. J. M., Nilsson, S., Gustafsson, J-A., Kusher, P. J., and Scanlon, T. S. Differential ligand activation of estrogen receptors ERa and ERb at AP-I sites. Science (Washington DC), 277: 1508-1510. 1997.